Endothelial progenitor cells and coronary artery disease: Current concepts and future research directions

Table 2 Clinical outcomes with endothelial progenitor cell stents

Ref.	Article	Patients, n	Inclusion criteria	Major clinical outcomes
Sung et al[75], 2018	Five-yr clinical and angiographic follow-up outcomes of intracoronary transfusion of circulation-derived CD34+ cells for patients with end-stage diffuse coronary artery disease unsuitable for coronary intervention phase 1 clinical trial	38	Death from any cause/major adverse cardiac and cerebrovascular event/target vessel revascularization/newly onset atrial fibrillation	Five-yr clinical outcomes: Noncardiovascular death: 13.2%. Cardiovascular death: 7.9%. Acute myocardial infarction: 7.9%. Newly onset atrial fibrillation: 2.6%
Sarno et al[85], 2017	Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish coronary angiography and angioplasty registry (SCAAR)	42357	Clinical presentation/lesion characteristics	One-yr outcomes: Restenosis: 1.1%; Restenotic lesion: 3.8%; Death: 5.2%
den Dekker et al[87], 2011	Final results of the HEALING IIB trial to evaluate a bio-engineered CD34 antibody-coated stent (Genous stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients	100	Angiographic features/ MACCE rate	Two-yr clinical outcomes: MACCE: 16.6%, MI: 5.2%, TLR clinically driven: 11.5%, TVF: 14.6%, Stent thrombosis: 3.1%
Chandrasekhar et al[88], 2020	1-year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry	2279	One-yr TLF/target lesion revascularization/ST/major adverse cardiac events	One-yr outcomes: TLF: 6.7%, Cardiac death: 2.4%, MI: 2.9%, TLR: 3.1%, Stent thrombosis: 1.8%

MACCE: Major adverse cardiac and cerebrovascular events; MI: Myocardial infarction; TLR: Target lesion revascularization; TVF: Target vessel failure; TLF: Target lesion failure.